|
|
|
|
|
|
|
|
|
|
|
 
|
Pancreas Cancer
News and Archives |
|
|
Kosan and Roche Present Favorable
Phase I Results of KOS-862 (Epothilone D), at the American Society
of Clinical Oncology Annual Meeting Kosan Biosciences Incorporated and Roche announced today results of the initial Phase I clinical trial of KOS-862 (Epothilone D) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. KOS-862 is a polyketide natural product that inhibits cancer cells by the same mechanism as paclitaxel, and is also effective against paclitaxel-resistant tumors in preclinical models. The poster entitled "KOS-862 (Epothilone D): A Comparison of Two Schedules in Patients with Advanced Malignancies" will be presented today, from 9:00 a.m. to 1:00 p.m., Central Time, at the McCormick Convention Center. ...full article |
||
|
||
|
For educational
purposes only; not to be relied upon Please read Pancreatica Disclaimer |
||
 Home | In The News | Links | Newswire | Donations FAQ | Clinical Trials Database | Research Resources | About Us |
||
|
|
||
|
www.pancreatica.org |
||